Bone Biologics
BBLG
10 hedge funds and large institutions have $470K invested in Bone Biologics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
992% more capital invested
Capital invested by funds: $43K → $470K (+$427K)
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
400% more funds holding
Funds holding: 2 → 10 (+8)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$484K |
| 2 |
Walleye Capital
New York
|
+$325K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.3K |
| 4 |
Millennium Management
New York
|
+$18.6K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $259K | +$484K | +859 | New |
|
|
2
Walleye Capital
New York
| $170K | +$325K | +577 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $10.7K | +$20.3K | +36 | New |
|
|
4
Millennium Management
New York
| $10K | +$18.6K | +33 | New |
|
|
WAM
5
Warberg Asset Management
Winnetka,
Illinois
| $6.29K | +$11.8K | +21 | New |
|
6
UBS Group
Zurich,
Switzerland
| $3.21K | +$6.2K | +11 | New |
|
|
VF
7
Virtu Financial
New York
| $3K | +$6.2K | +11 | New |
|
|
HF
8
HRT Financial
New York
| $3K | +$6.76K | +12 | New |
|
|
CAN
9
Cetera Advisor Networks
El Segundo,
California
| $2.2K | +$3.94K | +7 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $2K | +$563 | +1 | +20% |
|
11
Wells Fargo
San Francisco,
California
| $10 | – | – | – |
|
12
Morgan Stanley
New York
| $2 | – | – | – |
|
|
13
Vanguard Group
Malvern,
Pennsylvania
| – | -$35K | -23 | Closed |
|
BBLG Hedge Fund Activity: Q4 2022 in Review
10 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q4 2022, worth a combined $470K — up 992% from $43K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BBLG positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $484K. The largest seller was Vanguard Group, exiting entirely with an estimated $35K sold.
- 10 institutional investors held Bone Biologics (BBLG) as of Q4 2022, up from 2 in Q3 2022.
- Funds reported $470K of Bone Biologics stock for Q4 2022, up 992% quarter-over-quarter.
- 9 funds opened new Bone Biologics positions in Q4 2022 and 1 closed out, a net change of +8 holders.
- The largest Bone Biologics buyer in Q4 2022 was Sabby Management, an estimated $484K added.
- The largest Bone Biologics seller in Q4 2022 was Vanguard Group, an estimated $35K sold.
Based on aggregated 13F filings for Q4 2022.